OncoMed Pharmaceuticals, Inc. , a clinical-stage company developing novel therapeutics that target cancer stem cells , or tumor-initiating cells, today announced that patient dosing has begun in the randomized, placebo-controlled Phase 2 portion of the company's " ALPINE " clinical trial of its anti-Notch 2/3 cancer stem cell antibody, tarextumab , ... (more)
http://ift.tt/1oI47dd
http://ift.tt/1oI47dd
No comments:
Post a Comment